La vendita allo scoperto per NeuroMetrix dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di NeuroMetrix. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

NeuroMetrix (NASDAQ:NURO) Azioni, Report sulle vendite allo scoperto

NeuroMetrix

NeuroMetrix Inc is a commercial-stage healthcare company. Its core business activities are integrated with in-house capabilities spanning product development, manufacturing, regulatory affairs and compliance, sales and marketing, and customer support. The company produces bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The product line of the company includes Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The company operates in a single segment being Medical equipment and consumables.

NeuroMetrix Inc

Earnings

News

Health Care

General

NURO

NeuroMetrix Reports Q3 2024 Sales Of $0.6M Vs. $1.2M YoY, With EPS Loss Of $(0.75) Compared To ($1.66) YoY

NeuroMetrix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NURO#NASDAQ">NURO</a>) today for the purpose of clarity, reiterated that the Company is engaged in a review of strategic alternatives. &nbsp;
In February of this year, the Company announced that it had initiated a review of strategic options with an objective of enhancing shareholder value. Over the past 6 months, the Company has invested considerable effort in evaluating a number of specific strategic directions and also making financial, operational and commercial optimizations.
<ul>
<li>In collaboration with a financial advisor, the Company conducted an extensive survey of potential transactions. Detailed diligence was performed on multiple opportunities; however, the Company determined that none of these opportunities were in the best interests of its shareholders at this time.</li>
<li>The Company implemented a substantial reduction-in-force at the end of Q1 to lower operating expenses by over $0.5M per quarter.</li>
<li>The Company is engaged in discussions to sell certain international assets that are not central to the Company's core domestic focus.
<ul>
<li>The Company reported cash and cash equivalents of $16.4M for the quarter ended June 30, 2024.</li>
</ul>
</li>
</ul>

Asset Sales

NeuroMetrix Reiterates Its Review Of Strategic Alternatives; In Collaboration With A Financial Advisor, The Company Conducted An Extensive Survey Of Potential Transactions; Implemented A Substantial Reduction-In-Force At The End Of Q1 To Lower Operating Expenses By Over $500K Per Quarter; Is Engaged In Discussions To Sell Certain International Assets That Are Not Central To The Company's Core Domestic Focus

NeuroMetrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NURO#NASDAQ">NURO</a>) reported quarterly losses of $(0.74) per share. This is a 51.32 percent increase over losses of $(1.52) per share from the same period last year. The company reported $769.00 in sales this quarter. This is a 99.95 percent decrease over sales of $1.65 million the same period last year.

NeuroMetrix Q2 EPS $(0.74) Up From $(1.52) YoY, Sales $769,148 Down From $1.65M YoY

NeuroMetrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NURO#NASDAQ">NURO</a>) reported quarterly losses of $(1.67) per share. This is a 1.83 percent decrease over losses of $(1.64) per share from the same period last year. The company reported $1.09 million in sales this quarter. This is a 36.64 percent decrease over sales of $1.73 million the same period last year.

NeuroMetrix Q1 EPS $(1.67) Down From $(1.64) YoY, Sales $1.09M Down From $1.73M YoY

NeuroMetrix Q1 Revenue $1.093M Down From $1.724M YoY

<h3>Gainers</h3>
<ul>
<li>Mobile-health Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) shares increased by 34.7% to $27.44 during Friday's regular session. The market value of their outstanding shares is at $932.9 million. </li>
<li>NKGen Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) stock increased by 19.76% to $1.03. The company's market cap stands at $23.4 million. The company's, Q4 earnings came out 3 days ago. </li>
<li>Kintara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) stock increased by 18.57% to $0.13. The market value of their outstanding shares is at $4.9 million. </li>
<li>NeuroMetrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NURO#NASDAQ">NURO</a>) stock moved upwards by 17.26% to $4.28. The company's market cap stands at $8.5 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares moved upwards by 17.24% to $0.05. The company's market cap stands at $4.1 million. </li>
<li>Adlai Nortye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANL#NASDAQ">ANL</a>) stock moved upwards by 16.33% to $12.39. The company's market cap stands at $457.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SeaStar Medical Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) shares decreased by 21.2% to $0.43 during Friday's regular session. The company's market cap stands at $32.0 million. As per the press release, Q4 earnings came out 3 days ago. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) stock decreased by 20.81% to $0.33. The company's market cap stands at $3.0 million. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) shares decreased by 18.35% to $5.34. The market value of their outstanding shares is at $203.5 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock declined by 17.63% to $4.3. The company's market cap stands at $55.9 million. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) shares declined by 15.6% to $0.92. The market value of their outstanding shares is at $19.8 million. </li>
<li>Concord Medical Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>) shares declined by 14.25% to $0.5. The market value of their outstanding shares is at $21.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AEON

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

ISPC

Kintara Therapeutics, Inc. - Common Stock

KTRA

MNDR

NKGN

12 Health Care Stocks Moving In Friday's Intraday Session

NeuroMetrix Appoints Joshua S. Horowitz As New Independent Director; Co. Also Terminates At-The-Market Equity Facility

Biotech

NeuroMetrix Publishes Study Demonstrating That DPNCheck Diagnoses Diabetic Peripheral Neuropathy

NeuroMetrix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NURO#NASDAQ">NURO</a>) today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in December 2022.
"We have been pleased by the positive response to Quell Fibromyalgia from providers taking care of patients with fibromyalgia during our strategic launch phase," said Shai N. Gozani, M.D., Ph.D., Chief Executive Officer of NeuroMetrix. "This early adoption affirms the need for novel clinical options to support fibromyalgia patients."
Dr. Anjuli Desai, dual board certified in Pain Medicine and Physical Medicine and Rehabilitation, commented, "Quell Fibromyalgia has been the treatment option that I have been awaiting for fibromyalgia. It offers me a medication free, safe and effective treatment for a chronic condition that has proven to be a challenge to manage in the past."
Dr. Jeremy Adler, COO of Pacific Pain Medicine Consultants, stated that "For patients with Fibromyalgia, navigating treatments can be overwhelming, costly and carry significant side effects. It is great to have a non-medication option, backed by data, that may provide needed relief. In my practice, we have even had some patients report they were able to reduce pain with Quell Fibromyalgia that medications have never helped before."
Quell Fibromyalgia Indications
Quell Fibromyalgia is a transcutaneous electrical nerve stimulation (TENS) device indicated as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity. The device may be used during sleep.
Limitations The sale, distribution, and use of Quell Fibromyalgia is restricted to prescription use in accordance with 21 CFR 801.109. The Product labeling should be reviewed for a complete list of contraindications, precautions and warnings. For more information visit <a href="https://www.globenewswire.com/Tracker?data=yG2fq1-5jEHHu0Y10IHBpTPBJe6Oo_ZHEnme7cgpV3G9NnVgafSYxlBcU_1fpagLyF7es0fLsC1Hcgw15TKoVYOk6W-HqUad7xlX7oEifKk=">QuellFibromyalgia.com</a>.

NeuroMetrix Announces That Over 2000 Patients With Fibromyalgia Have Been Prescribed Quell Fibromyalgia

- Stock trades significantly below its net cash per share
- Questions the Board's ability and/or desire to create shareholder value
- Notes tremendous destruction of shareholder value under company's leadership
- Sees no reason for company to remain public
NEW YORK, NY / ACCESSWIRE / March 4, 2024 / On February 27, 2024, Ephraim Fields of Echo Lake Capital filed a Schedule 13D which included a letter to the Board of Directors of Neurometrix, Inc. <a href="https://pr.report/fDMzuaC2">(NASDAQ:</a><a href="https://www.benzinga.com/stock/NURO#NASDAQ">NURO</a>). The letter described his belief that the company should immediately liquidate because its stock price is trading significantly below net cash and because Mr. Fields sees no reason why the company should remain public. Among other things, the letter also questioned the Board's decision to issue stock at prices below net cash and its desire to create shareholder value.
A full copy of the letter can be found below:
CONTACT: Ephraim Fields <a href="mailto:ef@echolakecapital.com">ef@echolakecapital.com</a>
###
February 27, 2024
To the Board Of Directors:
As of December 31, 2023, NeuroMetrix had approximately $18.0 million of net cash and approximately 1.5 million shares outstanding, which equates to approximately $12.00 of net cash per share. Despite having all this net cash, plus assets that have some value and no significant liabilities, NURO's stock trades at only $3.50 per share or at a 70% discount to its net cash.
We believe the stock's dramatic undervaluation is largely attributable to the perception that you are not acting in the best interests of shareholders. Your incentives do not appear to be aligned with those of all shareholders because you personally own very few shares (despite your many years of service at the company and the generous compensation you have received).
We believe investors' concerns about your motivations have been recently heightened because:
<ol>
<li>You continue to permit NURO to issue shares via an ATM offering even though the stock is trading at a massive discount to its net cash and the company appears overcapitalized, not undercapitalized. We wonder why you think it is smart to issue equity at these prices?</li>
<li>You initiated a strategic review process to "promote growth and maximize shareholder value." To be clear, we have never, ever, seen such a dual mandate review process like the one you have initiated. We believe your primary fiduciary responsibility is to maximize shareholder (which can be accomplished in many ways including growing the company, shrinking the company or liquidating the company). Therefore, we are surprised that the review process is not limited to only maximizing shareholder value and that it also includes a mandate to "promote growth" (which may actually destroy shareholder value).</li>
</ol>
It is abundantly clear to us that it would be in shareholders' best interests if you were to immediately liquidate the company. We see no reason for NURO to remain public because the company is too small, its products have questionable growth prospects, corporate overhead is ridiculously high and the investment community has little confidence in your ability and/or desire to create shareholder value. Liquidating the company today would return the greatest amount of capital to shareholders in the shortest amount of time while exposing shareholders to the least amount of risk.
We believe you may be tempted to merge NURO with another company; However, we believe that would be a terrible mistake because it would be highly risky and would return no capital to your long-suffering shareholders.
Considering how much money shareholders have lost under your leadership and how much money you have personally made while shareholders have suffered greatly, we doubt many shareholders would be supportive of NURO remaining public and making an acquisition. We believe shareholders would overwhelmingly support our suggestion to immediately liquidate the company and return all proceeds to shareholders.
We hope you will accept our advice and immediately announce a liquidation plan without us having to take additional public action. If you have any questions, please do not hesitate to contact us.
Sincerely,
Ephraim Fields Echo Lake Capital

Management

Echo Lake Capital Calls For The Liquidation Of Neurometrix, Inc. "Notes Tremendous Destruction Of Shareholder Value Under Co's Leadership; Sees No Reason For Co To Remain Public"

NeuroMetrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NURO#NASDAQ">NURO</a>) reported quarterly losses of $(1.43) per share. This is a&nbsp;decrease over losses of $(0.73) per share from the same period last year. The company reported $1.32 million in sales this quarter. This is a 28.70 percent decrease over sales of $1.85 million the same period last year.

NeuroMetrix Q4 EPS $(1.43) Down From $(0.73) YoY, Sales $1.32M Down From $1.85M YoY

KYMR

LASR

LAUR

LILA

LNTH

MAIN

MELI

MGPI

MITT

MODV

MORN

MRIN

MRNA

MRVI

NABL

NICE

NMRK

NTLA

NVCR

NVEE

OLED

ONTF

OPCH

PKST

PLNT

PLYA

PODD

POOL

PRMW

RCEL

RLAY

RMAX

RYTM

SHYF

SMSI

SNBR

SPXC

STWD

TALK

TECK

THRY

TPIC

UPBD

UPLD

VALE

VCYT

VICI

VICR

WTRG

XPEL

ZEUS

Earnings Scheduled For February 22, 2024

NeuroMetrix 13G Filing Shows RS Fund LP Reported A 14.4% Stake In The Co As Of February 13, 2024

NeuroMetrix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NURO#NASDAQ">NURO</a>), a commercial stage medical device company focused on reducing the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices, today announced a process to review strategic options to promote growth of its Quell&#xAE; neuromodulation and DPNCheck&#xAE; neurodiagnostic businesses and to maximize shareholder value. &nbsp;
The Company plans to consider a wide range of options, including changes in marketing strategies, the acquisition of new assets, potential sale of Company assets, and merger or other strategic transactions. As the Company explores these strategic options there will be no change in the Company's commercial operations.
The Company has engaged Ladenburg Thalmann &amp; Co. as its financial advisor to assist in this process. There can be no assurance that this process will result in the Company pursuing or consummating any particular transaction or other strategic outcome. The Company has not set a timetable for completion of this evaluation process and may not disclose further developments unless disclosure is appropriate or necessary.
"There are attractive opportunities for both vertical and horizontal growth with our Quell neuromodulation technology," said Shai N. Gozani, M.D., Ph.D., CEO of NeuroMetrix. "Our recent investor presentation at the January Emerging Growth Conference provides a more in-depth discussion (<a href="https://www.globenewswire.com/Tracker?data=8dRuDYQncBzQ-EBW8NRnRCfGPYfr6kKn66xVSXSPA5T2Rz4QYlXsealwB4ZTJwThguoCzxRfmASa0-DWxNKBLAY-F2IfDQJO-Srh7mYNNT5w5nuYqUNuBNY72hTWPmQnZUWNJG5dslaILKbBUO4YXA==">https://www.youtube.com/watch?v=KdtYaTr2rjo</a>). We are also reviewing our DPNCheck business in light of the fundamental Medicare Advantage risk adjustment changes implemented by CMS last year. Growth initiatives consume financial resources and, in the near-term, we are fortunate to have adequate funding. However, our perspective extends beyond the near term. We intend to continue carefully managing our liquid resources, optimizing cash flow and taking advantage of funding opportunities. The exploration of strategic options is intended to complement these efforts with the goal of best positioning the Company for growth while optimizing shareholder interests."

NeuroMetrix Announces Review Of Strategic Options To Promote Growth Of Its Quell Neuromodulation And DPNCheck Neurodiagnostic Businesses And To Maximize Shareholder Value

The presentation was made at the National Science Foundation (NSF) funded Center to Stream Healthcare In Place (C2SHIP) annual meeting in Washington DC. The trial was conducted at the Baylor College of Medicine in collaboration with C2SHIP. The principal investigator was Dr. Bijan Najafi, Professor of Surgery, and clinical director at the Division of Vascular Surgery and Endovascular Therapy, Baylor College of Medicine. &nbsp;

NeuroMetrix Reported The Recent Presentation Of Data From A Clinical Trial Of Quell Wearable Neuromodulation Technology In Patients With Post-Acute Covid-19 Syndrome

NeuroMetrix Announces Peer-Reviewed Publication Of Phase 2 Clinical Trial Showing that Quell Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy

Trading Ideas

NeuroMetrix Shares Resume Trade

Stock Split

NeuroMetrix Shares To Resume Trade At 9:00 A.M.. ET

NeuroMetrix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nuro#NASDAQ">NURO</a>) today announced that it will effect a one-for-eight reverse split of its common stock, effective at 5:00 pm on November 21, 2023 (the "Effective Time"). The shares underlying the Company's outstanding options will also be adjusted accordingly.
The reverse stock split is intended to increase the per share trading price of the Company's common stock to satisfy the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. As a result of the reverse stock split, every eight shares of the Company's common stock issued and outstanding at the Effective Time will be consolidated into one issued and outstanding share, with no change in the nominal par value per share of $0.0001. No fractional shares will be issued as a result of the reverse stock split. Shareholders who otherwise would be entitled to receive a fractional share in connection with the reverse stock split will receive a cash payment in lieu thereof at a price equal to that fractional share to which the shareholder would otherwise be entitled multiplied by the closing price of the common stock on the Nasdaq Capital Market, as adjusted for the reverse stock split, on November 21, 2023. The Company's number of authorized shares of common stock will remain at 25,000,000 shares.
Trading of the Company's common stock on the Nasdaq Capital Market will continue, on a split-adjusted basis, with the opening of the markets on Wednesday, November 22, 2023, under the new CUSIP number 641255880 and the symbol "NURO". Immediately subsequent to the reverse stock split, there will be approximately 1,091,675 shares of the Company's common stock issued and outstanding.

Penny Stocks

NeuroMetrix Announces 1-For-8 Reverse Stock Split

<h3>Gainers</h3>
<ul>
<li>Comera Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMRA#NASDAQ">CMRA</a>) stock increased by 11.6% to $0.28 during Friday's after-market session. The company's market cap stands at $8.5 million. The company's, Q3 earnings came out yesterday. </li>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) stock rose 9.51% to $0.26. As per the press release, Q3 earnings came out yesterday. </li>
<li>Aravive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAV#NASDAQ">ARAV</a>) stock rose 9.44% to $0.14. Aravive's trading volume hit 68.8K shares by close, accounting for 0.7% of its average volume over the last 100 days. The market value of their outstanding shares is at $10.0 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) stock increased by 8.67% to $2.13. The market value of their outstanding shares is at $1.2 million. </li>
<li>Co-Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) stock rose 7.89% to $1.23. The company's market cap stands at $37.8 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Oncternal Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCT#NASDAQ">ONCT</a>) shares rose 7.82% to $0.31. The company's market cap stands at $18.4 million. As per the press release, Q3 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>XTL Biopharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTLB#NASDAQ">XTLB</a>) shares decreased by 14.1% to $0.79 during Friday's after-market session. The company's market cap stands at $4.3 million. </li>
<li>NeuroMetrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NURO#NASDAQ">NURO</a>) shares decreased by 11.01% to $0.44. Trading volume for this security closed at 245.5K, accounting for 637.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.8 million. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) shares declined by 10.82% to $0.21. TRACON Pharma's trading volume hit 20.1 million shares by close, accounting for 2086.9% of its average volume over the last 100 days. The market value of their outstanding shares is at $6.3 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares declined by 7.95% to $0.27. Jaguar Health's trading volume hit 146.7K shares by close, accounting for 3.6% of its average volume over the last 100 days. The market value of their outstanding shares is at $5.1 million. </li>
<li>Intelligent Bio Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBS#NASDAQ">INBS</a>) stock fell 7.43% to $0.53. Today's trading volume for this security ended up closing at 14.7 million shares, which is 380.1 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $2.4 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) stock fell 5.61% to $0.27. The company's market cap stands at $7.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARAV

CMRA

CODX

Intelligent Bio Solutions Inc. - Common Stock

INBS

JAGX

ONCT

SBFM

SNES

SXTC

TCON

XTLB

12 Health Care Stocks Moving In Friday's After-Market Session

Neurometrix (NURO) has shared an update. NeuroMetrix, Inc. has announced the appointment of Joshua Horowitz to its Board of Directors, where he'll ...

NeuroMetrix Board Appointment and Equity Program Termination

NeuroMetrix names new independent director, terminates equity program; shares up

Predictive Oncology, BIMI Holdings, IMAC Holdings among healthcare movers

NeuroMetrix GAAP EPS of -$1.67

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
NeuroMetrix (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuro-stock-quote/">NURO</a>) just reported results for the first quarter of 2024.<ul><li>NeuroMetrix reported earnings per share of -$1.67.</li><li>The company reported revenue of $1.09 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/nuro-stock-earnings-neurometrix-for-q1-of-2024/">NURO Stock Earnings: NeuroMetrix Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

NURO Stock Earnings: NeuroMetrix Reported Results for Q1 2024

NeuroMetrix GAAP EPS of -$0.74, revenue of $0.8M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
NeuroMetrix (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuro-stock-quote/">NURO</a>) just reported results for the second quarter of 2024.<ul><li>NeuroMetrix reported earnings per share of -74 cents.</li><li>The company reported revenue of $769,148.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/nuro-stock-earnings-neurometrix-for-q2-of-2024/">NURO Stock Earnings: NeuroMetrix Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

NURO Stock Earnings: NeuroMetrix Reported Results for Q2 2024

NeuroMetrix, Inc. (NURO) Q2 2024 Earnings Call Transcript

NeuroMetrix reports Q3 results

Neurometrix ( ($NURO) ) has released its Q3 earnings. Here is a breakdown of the information Neurometrix presented to its investors. NeuroMetrix, I...

NeuroMetrix Q3 2024: Mixed Results Amid Strategic Review

ALLR

BACK

BIMI

INVO

POAI

ZCMD

Press Releases

Echo Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be Fired

NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia

NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy

Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)

Contracts

NeuroMetrix Announces Steps Taken to Enhance Shareholder Value

NeuroMetrix Reports Q1 2024 Business Highlights

NeuroMetrix, Inc. Announces Date for Second Quarter 2024 Business Highlights Conference Call

NeuroMetrix Reports Q2 2024 Business Highlights and Update on Review of Strategic Options

Comments

NeuroMetrix

Vendite allo scoperto

NeuroMetrix (NASDAQ:NURO) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO